Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process

Mileidy Gonzalez1*, Anthony L. DeVico2 and John L. Spouge1

Abstract
Recently, Oberle et al. published a paper in Retrovirology evaluating the question of whether selection plays a role in HIV transmission. The Oberle study found no obvious genotypic or phenotypic differences between donors and recipients of epidemiologically linked pairs from the Swiss cohort. Thus, Oberle et al. characterized HIV-1 B transmission as largely “stochastic”, an imprecise and potentially misleading term. Here, we re-analyzed their data and placed them in the context of transmission data for over 20 other human and animal trials. The present study finds that the transmitted/founder (T/F) viruses from the Swiss cohort show the same non-random genetic signatures conserved in 118 HIV-1, 40 SHIV, and 12 SIV T/F viruses previously published by two independent groups. We provide alternative interpretations of the Swiss cohort data and conclude that the sequences of their donor viruses lacked variability at the specific sites where other studies were able to demonstrate genotypic selection. Oberle et al. observed no phenotypic selection in vitro, so the problem of determining the in vivo phenotypic mechanisms that cause genotypic selection in HIV remains open.

Keywords: Transmitted/founder virus, T/F, Transmission signatures, Selection during HIV transmission, Phenotypic versus genotypic selection
conclusions inevitably hold the caveat that in vitro assays may not be able to detect the in vivo selective pressures on viral genotypes.

“Stochastic” is an imprecise term when applied to HIV transmission

A "stochastic process" is a random function. In the context of HIV transmission, it entails a probability model for random variables changing over time. The conclusion of “stochastic” transmission therefore only implies some degree of randomness, and it does not exclude biological selection. If a study concludes that transmission is “stochastic”, therefore, it should probably conclude more accurately (and certainly more clearly) that it did not detect selection. In fact, a precise statistical framework to test for selection asks the question: are T/F viruses chosen uniformly at random from the donor pool? The null hypothesis for statistical testing is therefore that T/F viruses are chosen uniformly at random from the donor pool.

Absence of evidence is not evidence of absence

This popular aphorism summarizes our main objection with the conclusions of the Oberle study. Absence of evidence, or the failure to observe evidence supporting a hypothesis in a specific circumstance, is not necessarily broad evidence against the hypothesis. Thus, absence of selection (in a specific set of in vitro tests applied to a specific set of donor–recipient pairs) does not constitute evidence against selection and in favor of a uniform random process for all subtype B HIV-1 transmissions. Selection might even be playing a direct role in the transmissions in the Oberle study, but may not be evident perhaps because of unsuitable data, resolution, algorithms, tools, etc. The conclusions of the Oberle study therefore need to be appropriately qualified.

Failure to reject the null hypothesis is not the same as accepting it

In science, it is standard to calculate p values. When a p value is significant, by convention, we reject the null hypothesis (e.g., $H_0$ = T/F viruses are chosen uniformly at random from the donor pool). Insufficiently significant p values, as was the case for the comparisons in the Oberle study, are not enough to accept the null hypothesis. Data may simply be too sparse or inappropriate to detect weak trends supporting an alternative hypothesis (e.g., $H_A$ = T/F viruses are under selection).

Signatures in T/F viruses have already demonstrated selection during HIV transmission

The authors state: “To what extent HIV-1 transmission is a stochastic process or driven by selective forces that allow T/F viruses best to overcome bottlenecks in transmission has not been conclusively resolved.” In fact, the available literature on this subject consistently shows envelope sequence bias during transmission. Gnana-karan et al. [2] identified one signature in the Env signal peptide. We also identified four strong gp120 signatures conserved in T/F viruses from twelve different HIV-1, SHIV, and SIV trials [3]. Figure 1a illustrates our previous signature analysis on one of the SIV animal trials. The signature scanning algorithm identified that SIV T/F viruses were almost invariably Ile[33]–Ala[55]–Lys[57]–Asn[88] variants, despite I-A-K-N being a minor variant in the stock (2%). V-T-R-S constituted the major variant in the stock (79%); yet, none of the T/F viruses featured those residues at the signature sites (Fig. 1a). While other variants can sometimes transmit (e.g., IAKS), they do so infrequently and cannot compete in the presence of even miniscule proportions of I-A-K-N variants. Our findings of selection on T/F viruses were confirmed on data from four different vaccine trials by Smith et al. [4].

The A-[DK]-N signatures are conserved in HIV-1, SHIV, and SIV T/F Viruses

The extreme diversity of the SIVsmE660 stocks made it possible to observe selection at the transmission signature sites (Fig. 1a). Our previous report demonstrated statistical support for the I-A-K-N signatures from three different trials challenging vaccinated and unvaccinated animals with SIVsmE660O [3–6]. T/F viruses from other strains show diversity at site 33; thus, the I33 transmission signature seems peculiar to SIVsmE660 (Fig. 1b). We also showed that the signatures at sites 55, 57, and 88 are conserved in T/F viruses from SIVmac251, SHIVBal, and HIV-1 infections (Fig. 1b). The analogous signatures in HIV-1 and SHIV are A55-D57-N88. Note that we analyzed HIV-1 T/F viruses from subtype A [7], subtype B (the Step trial [8, 9], the Nairobi breastfeeding trial [10, 11], and Los Alamos database [2]), subtype C [12], subtype D [7], and subtype AID [7] and SHIV T/F viruses from three different sources [3, 13]. For the sake of the present analysis, the signature algorithm scanned additional T/F viruses from one other SHIVBal vaccine trial [14] and 13 infectious molecular T/F clones from the NIH AIDS reagents program. All T/F viruses have been collected in HIV-1, SHIV, and SIV show the A55-[DK]57-N88 signature regardless of sex, gender, vaccination status, viral dosage, or transmission route (Fig. 1b).

The T/F viruses of the Swiss Cohort also display the same conserved transmission signatures reported previously in other HIV, SHIV, and SIV T/F viruses

In accordance with the above findings, the signature scanning algorithm illustrated in Fig. 1a applied to the...
genetic data in the Oberle et al. study reveals that the A55, D57, and N88 envelope residues are selectively conserved in the T/F viruses of the Swiss cohort (Fig. 1c). Unfortunately, the diversity and sparsity of donor sequences in the Swiss cohort (Fig. 1c) precludes direct statistical elucidation of these residues/positions as for - mal transmission signatures. It is worth mentioning that 3% of the Swiss donor sequences differ at site 57: i.e., 3% of the non-transmitted donor viruses are [EN]57 variants whereas all the Swiss T/F viruses are D57 variants. Still, since A55-D57-N88 viruses constitute the major variant in the Swiss donor and T/F viruses (Fig. 1c) there is not enough variation in the Swiss cohort alone to gather statistical evidence in support of selection. The same caveats make it impossible to draw the opposite conclusion; i.e., that there is no selective pressure at these sites during transmission (see above). However, using the observations of the 170 other T/F viruses (118 HIV-1, 40 SHIV, and 12 SIV T/F viruses in Fig. 1b) as a framework, it is entirely plausible to interpret A55, D57, and N88 as non-random markers of T/F viruses in the Swiss cohort.

Conclusions
The Oberle et al. study found no evidence of phenotypic or genotypic selection in the transmitted viruses of the Swiss cohort; thus, the authors conclude that HIV transmission is largely “stochastic”. Here, we raise the issue that the breadth of their conclusions about the absence of selection in natural HIV transmission needs to be re-evaluated. On the one hand, it is well established that CCR5 tropism is a phenotypic determinant of HIV transmitted viruses indicating selection at the phenotypic level.

**Fig. 1** Transmission signatures conserved in SIV, SHIV, and HIV-1. a An alignment of two sequence logos representing Env sequences from an SIVsmE660 stock/inoculum (top) and the T/F (bottom) viruses establishing infections in four animals. The diagram illustrates the signature scanning protocol on one SIVsmE660 trial highlighting four signature sites: i.e., sites where the amino acid preference in the donor residue differs significantly from that of the T/F based on a Fisher Exact test. See our previous published work for statistical details of signature scanning in 11 other trials [3]. b Sequence logos tracking the signature residues in 170 T/F viruses from SIVsmE660, SIVmac251, SHIV-BaL, and HIV-1 (A, B, C, D, A1D). c An alignment of the donor (top) and T/F sequences from the study by Oberle et al. Sequence logos were generated using WebLogo software [16, 17]
Relatively limited diversity in donor sequences (in comparison to animal donor data) has been typical of every human trial thus far, which possibly results from limited sampling, shallow sequencing breadth, or from strong selection. The latter possibility is supported by findings that A55-[DK]57-N88 predominate also in database sequences of circulating variants from chronic infection [3, 4]. The A[DK]N motif seems to predominate in circulating HIV-1 and HIV-2 variants. Given the high mutation rates and viral turnover in HIV, such levels of conservation beyond transmission indicate strong selection for functional or structural fitness reasons.

Such observations indicate that the A55-[DK]57-N88 sites are “lethal”; specifically, introducing other residues therein extract an extreme fitness cost to the virus. What specific role the amino acid residues defining these putative markers have in increasing HIV transmission efficiency remains unclear. It should be noted that the genetic transmission signatures discussed above have yet to be directly linked with the phenotypic traits Oberle et al. analyzed in their cohort study. Accordingly, one interpretation of Oberle et al. is that the key phenotypic traits peculiar to HIV-1 T/F variants remain to be defined and could benefit from other advanced structural analyses, in situ imaging, and/or in vivo analyses of viral replication. Taken together, our evidence indicates that under phenotypic circumstances not examined in the Swiss cohort, HIV T/F viruses are undergoing selection.

Authors’ contributions
MG analyzed and interpreted the data. MG, ALD, and JLS wrote the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusions of this article are referenced in the text.

Funding
MG and JLS were supported by the Intramural Research Program of the NIH, National Library of Medicine. ALD was funded by grants from The Bill and Melinda Gates Foundation and NIAID, NIH.

Received: 17 November 2016   Accepted: 22 December 2016
Published online: 24 February 2017

References
1. Oberle CS, et al. Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology. 2016;13(1):62.
2. Gnanakaran S, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7(9):e1002209.
3. Gonzalez MW, et al. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission. J Virol. 2015;89(7):3619–29.
4. Smith SA, et al. Signatures in Simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques. J Virol. 2016;90(4):1880–7.
5. Keele BF, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med. 2009;206(11):1577–34.
6. Roederer M, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505(7484):502–8.
7. Baalwa J, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436(1):33–48.
8. Buchbinder SF, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93.
9. Rolland M, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17(3):366–71.
10. Ndubu R, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283(9):1167–74.
11. Wu X, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80(2):835–44.
12. Salazar-Gonzalez JF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273–89.
13. Klein K, et al. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol. 2013;87(21):11604–16.
14. Santra S, et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 2015;11(8):e1005042.
15. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657–700.
16. Crooks GE, et al. WebLogo: a sequence logo generator. Genome Res. 2004;14(6):1188–90.
17. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18(20):6097–100.